 |
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
U.S. Centers for Disease Control and Prevention
• News Briefs
AIDS Drug Will Be Offered in Poor Countries at CostApril 4, 2003 This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. Foster City, Calif.-based Gilead Sciences Inc. says it will
begin offering its AIDS drug Viread at cost to 68 of the world's
poorest countries. The drug maker will offer Viread to
"qualified" nations throughout Africa, as well as to 15 other
poor countries, for $1.30 per once-daily pill, or $475 a year. A
year's supply of Viread in the United States costs roughly
$4,300. Gilead said the lower price covers only its cost of
manufacturing the drug and overseeing distribution. While clinics
that wish to receive Viread must be accredited AIDS care
facilities, they will not have to work through local governments
to participate. AIDS activists called the program a welcome step
but noted that, like other AIDS drug access plans in developing
countries, it still falls short of the steps necessary to ensure
that million of AIDS patients receive the treatment they need.
Back to other CDC news for April 4, 2003 This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. Wall Street Journal 04.04.03 This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
|
E-Mail
Printable Single-Page
Glossary
Share
